Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02091141
Recruitment Status : Recruiting
First Posted : March 19, 2014
Last Update Posted : May 1, 2019
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.

Brief Summary:
This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.

Condition or disease Intervention/treatment Phase
Neoplasms Solid Tumors Biliary Cancer Salivary Cancer Bladder Cancer Drug: Trastuzumab Drug: Pertuzumab Drug: Erlotinib Drug: Vemurafenib Drug: Cobimetinib Drug: Vismodegib Drug: Alectinib Drug: Atezolizumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 765 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents
Actual Study Start Date : April 14, 2014
Estimated Primary Completion Date : September 30, 2020
Estimated Study Completion Date : March 31, 2021


Arm Intervention/treatment
Experimental: Trastuzumab Plus Pertuzumab
Participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion as loading dose, followed by 6 mg/kg IV infusion every 3 weeks; and pertuzumab 840 mg IV infusion as loading dose, followed by 420 mg IV infusion every 3 weeks.
Drug: Trastuzumab
Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Other Name: Herceptin

Drug: Pertuzumab
Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Other Name: Perjeta

Experimental: Erlotinib
Participants will receive erlotinib 150 milligrams (mg) orally once daily in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
Drug: Erlotinib
Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Other Name: Tarceva

Experimental: Vemurafenib Plus Cobimetinib
Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle; and cobimetinib 60 mg orally once daily for 21 days on and 7 days off in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
Drug: Vemurafenib
Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Other Name: Zelboraf

Drug: Cobimetinib
Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Other Name: Cotellic

Experimental: Vismodegib
Participants will receive vismodegib 150 mg orally once daily in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
Drug: Vismodegib
Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Other Name: Erivedge

Experimental: Alectinib
Participants will receive alectinib 600 mg orally BID in each 28-day cycle.
Drug: Alectinib
Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Other Name: Alecensa

Experimental: Atezolizumab
Participants will receive atezolizumab 1200 mg IV infusion every 3 weeks.
Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Other Name: Tecentriq




Primary Outcome Measures :
  1. Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator [ Time Frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 5 years) ]
    Tumor response will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for all arms.

  2. Percentage of Atezolizumab-Treated Participants With Tissue Tumor Mutational Burden (tTMB) ≥16 Mutations/Mb With Overall Response, as Assessed by the Independent Review Committee (IRC) [ Time Frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 5 years) ]
    Tumor response will be assessed using RECIST version 1.1.


Secondary Outcome Measures :
  1. Percentage of Participants With Disease Control [ Time Frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 5 years) ]
    Tumor response will be assessed using RECIST version 1.1 for all arms.

  2. Progression-Free Survival (PFS) [ Time Frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 5 years) ]
    Tumor response will be assessed using RECIST version 1.1 for all arms.

  3. Percentage of Participants who are Alive at Year 1 [ Time Frame: 1 year ]
  4. Duration of Response [ Time Frame: From the date of first documented response (complete response [CR] or partial response [PR]) to the time of disease progression or death from any cause, whichever occurs first (up to approximately 5 years) ]
    Tumor response will be assessed using RECIST version 1.1 for all arms.

  5. Percentage of Atezolizumab-Treated Participants with tTMB ≥10 Mutations/Mb and <16 Mutations/Mb With Overall Response, as Assessed by the Investigator [ Time Frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 5 years) ]
    Tumor response will be assessed using RECIST version 1.1.

  6. Percentage of Atezolizumab-Treated Participants with Blood Tumor Mutational Burden (bTMB) ≥16 Mutations With Overall Response, as Assessed by the IRC [ Time Frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (up to approximately 5 years) ]
    Tumor response will be assessed using RECIST version 1.1.

  7. Percentage of Participants With Adverse Events [ Time Frame: From first study treatment administration to 30 days (45 days for vismodegib, 90 days for atezolizumab) after the last dose (up to approximately 5 years) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

General Inclusion Criteria:

  • Life expectancy greater than or equal to (≥) 12 weeks
  • Histologically documented metastatic cancer (solid tumors, not including hematologic malignancies)
  • Participants who have received standard first-line therapy for metastatic cancer (except for the tumors for which no first-line therapy exists) and in whom a trial of targeted therapy is considered the best available treatment option. Eligible participants should not have available therapies that will convey clinical benefit and/or are not suitable options per the treating physician's judgment
  • No previous treatment with the specific assigned study drug or any other drug sharing the same target
  • Measurable disease by RECIST v1.1
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 (For patients enrolling in the atezolizumab arm, ECOG score must be documented within 7 days prior to first treatment and confirmation of ECOG PS must be entered into the interactive web response system [IWRS] prior to initiation of treatment)
  • Adequate hematologic, renal, and liver function as defined by the protocol
  • If applicable, use of contraception methods or abstinence as defined by the protocol

Study-Drug Specific Inclusion Criteria:

Trastuzumab plus Pertuzumab

  • Molecular testing results from clinical laboratory improvement amendments (CLIA)-certified laboratories (using tissue and/or blood) demonstrating HER2 overexpression or amplification. Participants must have one of the following tumor types: biliary cancer, salivary cancer, or bladder cancer

    a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment)

  • Left ventricular ejection fraction (LVEF) greater than (>) 50 percent (%) or above the lower limit of the institutional normal range, whichever is lower
  • Availability of an archival or new pre-treatment tissue sample is required if molecular testing was not performed by Foundation Medicine. Any available tumor tissue sample can be submitted. The tissue sample must be submitted within 4 weeks after enrollment

Erlotinib

  • Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating EGFR-activating mutations

Vemurafenib plus Cobimetinib

  • Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating BRAF V600 mutations a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment)

Vismodegib

  • Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating hedgehog pathway relevant mutation (activating mutation of smoothened [SMO] or loss-of-function mutation of protein patched homolog-1 [PTCH-1])

    a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment)

  • All non-hematological adverse events related to any prior chemotherapy, surgery, or radiotherapy must have resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade less than or equal to (≤) 2 prior to starting therapy

Alectinib

  • Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating anaplastic lymphoma kinase (ALK) gene rearrangements, ALK mutations, ALK copy number gain or (for melanoma only) increased ALK expression or presence of ALK-alternative transcription initiation transcript (ALKATI) a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment)

Atezolizumab

  • Molecular testing results from CLIA-certified laboratories (using tissue) demonstrating elevated tissue tumor mutational burden (tTMB ≥10 mutations/ Megabase [Mb])
  • For patients where molecular testing was not performed using Foundation Medicine, submission of an archival or new pretreatment tissue sample is mandatory. For patients where molecular testing was performed using Foundation Medicine, submission of an archival or new pretreatment tissue sample is required, if available. The tissue sample must be submitted within 4 weeks after enrollment

General Exclusion Criteria:

  • Participants with hematologic malignancies
  • Concurrent administration of any other anti-cancer therapy (except male participants with prostate cancer receiving androgen blockade): Bisphosphonates and denosumab are allowed; Most recent anti-cancer therapy ≤28 days and have not recovered from the side effects, excluding alopecia; Radiation therapy within ≤14 days
  • Active or untreated brain metastases
  • History of carcinomatous meningitis
  • Uncontrolled concurrent malignancy (early stage is allowed if not requiring active therapy or intervention)
  • Pregnant or breastfeeding women, or intending to become pregnant during the study
  • Any significant cardiovascular events within 6 months prior to study entry
  • Pulmonary embolism within 30 days prior to study entry
  • History or presence of clinically significant ventricular or atrial dysrhythmia >Grade 2 per NCI CTCAE v4.0
  • Any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results
  • Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol

Study-Drug Specific Exclusion Criteria:

Trastuzumab plus Pertuzumab

  • Previous treatment with any HER2-targeted therapy

Erlotinib

  • Non-small cell lung cancer (NSCLC) or pancreatic cancer identified by exon 19 deletions or exon 21 L858R substitution mutations
  • EGFR amplifications in the absence of EGFR-activating mutations
  • Cancers with exon 20 mutations
  • Previous treatment with erlotinib or any other EGFR inhibitor
  • Inability to swallow pills
  • Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of erlotinib

Vemurafenib plus Cobimetinib

  • Malignant melanoma, papillary thyroid cancer, colorectal cancer, or hematologic malignancy including multiple myeloma
  • LVEF below institutional lower level of normal (LLN) or below 50%, whichever is lower
  • History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment, retinal vein occlusion (RVO), or neovascular macular degeneration
  • Presence of any of the following conditions, which are risk factors for RVO: Uncontrolled glaucoma with intraocular pressure >21 millimetres of mercury (mm Hg); Serum cholesterol ≥Grade 2; Hypertriglyceridemia ≥Grade 2; Hyperglycemia (fasting) ≥Grade 2; Grade ≥2 uncontrolled hypertension (participants with a history of hypertension controlled with anti-hypertensive medication to Grade </=1 are eligible)
  • Prior or concurrent malignancy with known RAS mutation
  • Previous treatment with vemurafenib or any other BRAF inhibitor (prior sorafenib is allowed)
  • Previous treatment with cobimetinib or any other mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitor
  • Prior treatment with a RAF inhibitor
  • Inability to swallow pills
  • Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of vemurafenib
  • History of congenital long QT syndrome or mean (average of triplicate measurements) corrected QT (QTc) measured using Fridericia's method ≥450 millisecond (ms) at baseline or uncorrectable abnormalities in serum electrolytes (sodium, potassium, calcium, magnesium, phosphorus)

Vismodegib

  • Basal cell carcinoma of the skin, medulloblastoma, small-cell lung cancer, or hematologic malignancies
  • Previous treatment with vismodegib or any other hedgehog pathway inhibitor
  • Inability to swallow pills
  • Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of vismodegib

Alectinib

  • ALK-positive NSCLC, neuroblastoma, and childhood tumors
  • Previous treatment with alectinib or any other ALK inhibitor
  • Participants with symptomatic bradycardia
  • Administration of strong/potent cytochrome P3A4 (CYP3A4) inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib
  • Inability to swallow pills
  • Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of alectinib

Atezolizumab

  • History of leptomeningeal disease
  • Uncontrolled tumor pain
  • Asymptomatic metastatic lesions that would likely cause functional deficits or intractable pain with further growth (e.g., epidural metastasis that is not currently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrollment
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters are allowed
  • Uncontrolled or symptomatic hypercalcemia
  • Previous treatment with atezolizumab or another programmed death-1 (PD-1)/PD-L1 inhibitor
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  • Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells
  • Known allergy or hypersensitivity to any component of the atezolizumab formulation
  • Active or history of autoimmune disease or immune deficiency
  • Prior allogeneic stem cell or solid organ transplantation
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Positive human immunodeficiency virus (HIV) test, active hepatitis B virus (HBV) infection, active hepatitis C virus (HCV) infection or active tuberculosis
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
  • Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
  • Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study
  • Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study or within 5 months after the final dose of atezolizumab
  • History of other malignancy within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer
  • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the participant at high risk from treatment complications
  • Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
  • Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of the drug (whichever is longer) prior to randomization
  • Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02091141


Contacts
Layout table for location contacts
Contact: Reference Study ID Number: ML28897 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global-roche-genentech-trials@gene.com

  Hide Study Locations
Locations
Layout table for location information
United States, Arizona
Western Regional Medical Center at Cancer Treatment Centers of America Recruiting
Goodyear, Arizona, United States, 85338
Mayo Clinic Arizona Recruiting
Phoenix, Arizona, United States, 85259
United States, Arkansas
Highlands Oncology Group Recruiting
Rogers, Arkansas, United States, 72758
United States, California
Science 37, Inc Completed
Culver City, California, United States, 90230
City of Hope Comprehensive Cancer Center Recruiting
Duarte, California, United States, 91010
Moores UCSD Cancer Center; Dept Clinical Trials Office Recruiting
La Jolla, California, United States, 92093-0698
Stanford Comprehensive Cancer Center Recruiting
Stanford, California, United States, 94305
United States, Colorado
University of Colorado Recruiting
Aurora, Colorado, United States, 80045-2517
United States, Connecticut
Yale Cancer Center Terminated
New Haven, Connecticut, United States, 06520
United States, Florida
SCRI Florida Cancer Specialists South Recruiting
Fort Myers, Florida, United States, 33916
Mayo Clinic Recruiting
Jacksonville, Florida, United States, 32224
Florida Hospital Cancer Inst; Memorial System Onc Clin Rsch Recruiting
Orlando, Florida, United States, 32804
Florida Cancer Specialist, North Region Recruiting
Saint Petersburg, Florida, United States, 33705
Florida Cancer Specialists, Research Department Recruiting
West Palm Beach, Florida, United States, 33401
United States, Georgia
University Cancer & Blood Center, LLC; Research Recruiting
Athens, Georgia, United States, 30607
Northeast Georgia Medical Center; Oncology Research Dept-5C Recruiting
Gainesville, Georgia, United States, 30501
Southeastern Regional Medical Center, Inc. Recruiting
Newnan, Georgia, United States, 30265
United States, Illinois
Northwestern University; Robert H. Lurie Comp Can Ctr; Northwestern Medicine Development Inst Recruiting
Chicago, Illinois, United States, 60611
University Of Chicago Medical Center; Section Of Hematology/Oncology Recruiting
Chicago, Illinois, United States, 60637
Midwestern Regional Med Center Recruiting
Zion, Illinois, United States, 60099
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting
Baltimore, Maryland, United States, 21287
United States, Minnesota
Mayo Foundation Recruiting
Rochester, Minnesota, United States, 55905
United States, Missouri
Research Medical Center - Antibiotic Research Associates, Inc. Recruiting
Kansas City, Missouri, United States, 64132
United States, New York
Weill Cornell Univ Medical Ctr; Breast Cancer Center Recruiting
New York, New York, United States, 10021
Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion Recruiting
New York, New York, United States, 10032
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
United States, North Carolina
Univ No Carolina School of Med; Physicians Office Bldg Recruiting
Chapel Hill, North Carolina, United States, 27599-7305v
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Wake Forest Univ Health Svcs; Internal Medicine Recruiting
Winston-Salem, North Carolina, United States, 27157
United States, North Dakota
Sanford Roger Maris Cancer Center Completed
Fargo, North Dakota, United States, 58102
United States, Ohio
Oncology Hematology Care Inc Recruiting
Cincinnati, Ohio, United States, 45242
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44106
University Hospitals of Cleveland Recruiting
Cleveland, Ohio, United States, 44106
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Southwestern Reg Med Ctr Inc Terminated
Tulsa, Oklahoma, United States, 74133
United States, Oregon
Providence Portland Medical Center Active, not recruiting
Portland, Oregon, United States, 97213
United States, Pennsylvania
Abramson Cancer Center Completed
Philadelphia, Pennsylvania, United States, 19104
Thomas Jefferson University Hospital Recruiting
Philadelphia, Pennsylvania, United States, 19107
Eastern Regional Medical Ctr Recruiting
Philadelphia, Pennsylvania, United States, 19124
UPMC - Hillman Cancer Center Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Abington Mem Hosp-Abington; Rose. Can Ctr,Gyn Onc Ins Recruiting
Willow Grove, Pennsylvania, United States, 19090
United States, South Dakota
Sanford Cancer Cnt Onco Clinic Recruiting
Sioux Falls, South Dakota, United States, 57104
United States, Tennessee
SCRI Tennessee Oncology Chattanooga Recruiting
Chattanooga, Tennessee, United States, 37404
West Clinic Recruiting
Germantown, Tennessee, United States, 38138
Tennessee Cancer Specialists Recruiting
Knoxville, Tennessee, United States, 37920
Tennessee Onc., PLLC - SCRI Recruiting
Nashville, Tennessee, United States, 37203
Vanderbilt Ingram Cancer Clinic Recruiting
Nashville, Tennessee, United States, 37232
United States, Texas
The Center for Cancer and Blood Disorders - Fort Worth Terminated
Fort Worth, Texas, United States, 76104
MD Anderson Recruiting
Houston, Texas, United States, 77030
United States, Virginia
Virginia Cancer Institute Completed
Richmond, Virginia, United States, 23226
United States, Washington
Northwest Medical Specialties Recruiting
Tacoma, Washington, United States, 98405
United States, Wisconsin
University of Wisconsin Recruiting
Madison, Wisconsin, United States, 53792
Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Genentech, Inc.
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Genentech, Inc.
ClinicalTrials.gov Identifier: NCT02091141     History of Changes
Other Study ID Numbers: ML28897
PRO 02 ( Other Identifier: Genentech, Inc. )
First Posted: March 19, 2014    Key Record Dates
Last Update Posted: May 1, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Trastuzumab
Pertuzumab
Erlotinib Hydrochloride
Atezolizumab
Vemurafenib
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs